Ebola hemorrhagic fever WHO "Two kinds of drugs are effective for treatment" August 13 at 10:44
With regard to Ebola hemorrhagic fever, which continues to be epidemic in Central Africa and the Democratic Republic of the Congo, WHO = World Health Organization has announced that two drugs under development have been shown to be effective in clinical trials, and it will be noticed whether it will lead to the convergence of the epidemic It is.
In the Democratic Republic of the Congo in central Africa, Ebola hemorrhagic fever has been prevalent since August last year in North Kivu Province in the east, and about 2800 cases have been confirmed so far, and about 1900 have died.
WHO has been conducting clinical trials for drugs that may be effective in treating Ebola since November last year, and on the 12th, it was announced that two kinds of drugs had excellent effects.
According to the research team, clinical trials were conducted on approximately 700 patients with four drugs, and the mortality rate of patients who received “REGN-EB3” developed by an American pharmaceutical company was 29%. NIAID = “MAb114” developed by the National Institute of Allergy and Infectious Diseases was 34%, showing a significant difference compared to the other two drugs.
In addition, 90% of the patients who were administered at the early stage of infection at a low virus concentration in the blood survived.
NIAID Dr. Anthony Fouch, who was involved in clinical trials, said that “both drugs are highly effective and is a major advance towards patient treatment,” and is expected to lead to the convergence of the epidemic. In the future, attention is paid to whether new outbreaks can be prevented.